51219-55-7

Basic information

• Product Name: 3-{[(benzyloxy)carbonyl]aMino}-3-Methylbutanoic acid
• Synonyms: 3-{[(benzyloxy)carbonyl]aMino}-3-Methylbutanoic acid;N-Cbz-3-amino-3-methylbutanoic acid
• CAS NO: 51219-55-7
• Molecular Formula: C₁₃H₁₇NO₄
• Molecular Weight: 251.27838
• Mol File: 51219-55-7.mol
• Article Data: 25

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3-{[(benzyloxy)carbonyl]aMino}-3-Methylbutanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-{[(benzyloxy)carbonyl]aMino}-3-Methylbutanoic acid(51219-55-7)
• EPA Substance Registry System: 3-{[(benzyloxy)carbonyl]aMino}-3-Methylbutanoic acid(51219-55-7)

Safety Data

• Hazardous Substances Data: 51219-55-7(Hazardous Substances Data)

Usage

General Description

3-{[(Benzyloxy)carbonyl]amino}-3-methylbutanoic acid is a complex organic compound that consists of a 3-Methylbutanoic acid backbone. It has been functionalized at one end of the compound with an amino group and protected by a benzyloxycarbonyl (Z) group. The benzyloxycarbonyl group is often used in organic chemistry and biochemistry to protect an amino group during the synthesis of peptide chains. However, the specific properties, uses, or role of this exact chemical compound may not be widely documented and it could be used in research or as a specific reactant for complex organic synthesis.

Upstream product

• 597-43-3 2,2-dimethylsuccinic acid 
• 54043-71-9 4-methoxy-2,2-dimethyl-4-oxobutanoic acid 
• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 
• 625-05-8 3-amino-3-methylbutanoic acid 
• 100-51-6 benzyl alcohol 
• 541-47-9 3-Methylbutenoic acid 
• 6300-94-3 5,6-dihydro-6,6-dimethyluracil 
• 75315-63-8 N-(benzyloxycarbonyl)succinimide 
• 128182-82-1 3-[Benzyloxycarbonylamino]-3-methylbutanoic acid,methyl ester 
• 501-53-1 benzyl chloroformate 

Downstream Products

• 1037832-97-5 2-(acetylthio)ethyl 3-(benzyloxycarbonylamino)-3-methylbutanoate 
• 1037832-98-6 2-(3-(benzyloxycarbonylamino)-3-methylbutanoyloxy)ethanesulfonic acid 
• 1322065-45-1 benzyl 4,6-dihydroxy-2-methylhexan-2-ylcarbamate 
• 1163298-06-3 C₁₃H₁₈N₂O₃ 
• 1080675-03-1 (2-dimethylcarbamoyl-1,1-dimethylethyl)-carbamic acid benzyl ester 
• 956473-00-0 3-benzyloxycarbonylamino-3-methylbutaneperoxoic acid 1-methoxy-1-methylethyl ester 
• 145457-70-1 3-benzyloxycarbonylamino-3-methyl-N[2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3(R)-yl]butanamide 
• 145554-02-5 3-benzyloxycarbonylamino-3-methyl-N-[2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3(R)-yl]-butanamide 
• 114359-54-5 (S)-2-(3-Benzyloxycarbonylamino-3-methyl-butyrylamino)-3-phenyl-propionic acid 
• 164864-45-3 (S)-2-(3-Amino-3-methyl-butyrylamino)-3-phenyl-propionic acid 
• 162356-94-7 3-Benzyloxycarbonylamino-3-methyl-N-[2,3,4,5-tetrahydro-2-oxo-1-[[2'-[(t-butoxycarbonylamino)methyl][1,1'-biphenyl]-4-yl]methyl]-1H-1-benzazepin-3(R)-yl]-butanamide 
• 197652-43-0 [1,1-Dimethyl-2-((R)-1-{2'-[(3-methyl-ureido)-methyl]-biphenyl-4-ylmethyl}-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-ylcarbamoyl)-ethyl]-carbamic acid benzyl ester 

Relevant articles and documents

GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF

The present invention relates to a glucopyranosyl derivative and a use thereof. In particular, the present invention relates to a glucopyranosyl derivative that is used as an inhibitor of sodium-dependent glucose transporters (SGLTs), particularly being used as an inhibitor of sodium-dependent glucose transporter-1 (SGLT1), and a pharmaceutically acceptable salt or stereoisomer thereof, further relating to a pharmaceutical composition containing the derivative. The present invention further relates to a use of the compound and a pharmaceutical composition thereof in the preparation of a drug for treating diabetes and diabetes-related diseases.

N,N-Dichloroaminosulfonic acids as novel topical antimicrobial agents

2-Dichloroamino-2-methyl-propane-1-sulfonic acid sodium salt (2a), a stable derivative of endogenous N,N-dichlorotaurine (1), has been identified and is under development as a topical antimicrobial agent. Structure-activity relationships of analogs were explored to achieve optimal antimicrobial activity with minimal mammalian toxicity while maintaining the desired stability. All the analogs synthesized showed antimicrobial activity against Staphylococcus aureus, Escherichia coli, and Candida albicans in the range of 1-128 μg/mL and cytotoxicity against mammalian L929 cells in the range 80-1900 μg/mL.

N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES

The present invention relates to active bactericidal, antibacterial, anti-infective, antimicrobial, sporicidal, disinfectant, antifungal and antiviral compounds and compositions and to new uses of these compositions in therapy. This specification also describes methods of use for the new compounds and compositions. The specification further describes methods for preparing these compounds.